Cartesian Therapeutics, Inc. announced compelling 12-month efficacy and safety data from its Phase 2b trial of Descartes-08 in participants with generalized myasthenia gravis (MG). The results showed that Descartes-08-treated participants sustained deep responses through long-term follow-up after a single course of therapy.
Participants experienced an average 4.8-point reduction in MG-ADL (Myasthenia Gravis Activities of Daily Living) at Month 12, indicating significant and lasting improvement in daily function. The most pronounced benefits were observed in a subgroup of participants who had not received prior biologic therapies, showing an average 7.1-point reduction in MG-ADL and 57% maintaining minimum symptom expression at Month 12.
The safety profile of Descartes-08 remained consistent with previously reported data, continuing to support its administration in an outpatient setting without the need for preconditioning chemotherapy. This robust long-term data reinforces the potential of Descartes-08 to transform the treatment landscape for MG, with the Phase 3 AURORA trial on track to dose its first patient in the second quarter of 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.